Pfizer vs. Merck and the Future of R&D

Two brand new CEOs take very different approaches to address the same problem: what to do about unrealistic expectations for growth in 2012. The different strategies chart different courses through a stressful period. We’ve seen this debate before, and it is hard to argue that either company prevailed last time around.